Supply chains are an integral part of getting a product to market and therapies to patients. Sumit Vakil at Resilinc discusses with EPC the role that resiliency plays in limiting disruptions to supply chains
EPC: What are some of the most significant risks facing pharma supply chains at the moment, and how can these be mitigated?
Sumit Vakil (SV): Let’s begin by talking about active pharmaceutical ingredients (APIs) and their origin: whether it is European or US-based pharma manufacturing, a significant proportion of APIs come from China or India. China has faced several supply chain disruptions and manufacturing shutdowns because of their past zero-COVID-19 policy. Now that the policy is gone, there has been a spike in their infection rate, which has caused an increasing amount of factory shutdowns. Certainly, shipping data from China is starting to slow – but it remains to be seen whether that’s because
of the zero-COVID-19 policy ending or because of an overall economic slowdown.
Similarly, India is another major source of APIs. However, Indian API manufacturers are also dependent on Chinese manufacturers for raw materials, creating a second level of dependency.